MedTrace Logo

Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration

NCT03971357 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2023-02-06

Study results available
· View outcomes & findings →

Summary

Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central endothelial cell layer.

Conditions

  • Fuchs' Endothelial Dystrophy

Interventions

DRUG

Netarsudil

netarsudil opthalmic solution 0.02%

DRUG

Placebo

Placebo eye drops

Sponsors & Collaborators

  • Price Vision Group

    lead INDUSTRY

Principal Investigators

  • Francis W Price, Jr, MD · Price Vision Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-22
Primary Completion
2021-08-26
Completion
2021-08-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03971357 on ClinicalTrials.gov